Inovio Pharmaceuticals, Inc. Aktie News

PLYMOUTH MEETING, Pa. , Oct. 31, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan (the "Inducement Plan").

PLYMOUTH MEETING, Pa. , Oct. 27, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancers, and infectious diseases, today announced that its third quarter 2025 financial results will be released after the market close on November 10, 2025.

PLYMOUTH MEETING, Pa. , Oct. 23, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced that it will participate in a virtual fireside chat at the upcoming Stephens Biotechnology Virtual Fireside Chat Conference.

Publication includes complete data for all participants (n=39) up to week 72, further demonstrating durable and tolerable expression of DMAbs Effective target binding and confirmed functional activity through week 72 No immune rejection of the DMAbs detected across ~1,000 blood samples Most common side effects were mild, temporary injection site reactions such as pain and redness; no serious ad...

PLYMOUTH MEETING, Pa. , Oct. 2, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan (the "Inducement Plan").

Several presentations to highlight key aspects of lead product candidate, INO-3107, as a potential treatment for Recurrent Respiratory Papillomatosis (RRP) Additional presentations focus on promise of next-generation DNA medicine technology, including the first preclinical data describing potential for DNA-encoded protein technology (DPROT) to address Hemophilia A PLYMOUTH MEETING, Pa. , Sept. ...

Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) H.C. Wainwright 27th Annual Global Investment Conference September 5, 2025 7:00 AM EDT Company Participants Jacqueline Shea - CEO, President & Director Conference Call Participants Katherine Degen Presentation Katherine Degen Good morning, and welcome to the H.C.

Complete submission of the Biologics License Application (BLA) remains on track for 2H25 with the goal of file acceptance by U.S. Food and Drug Administration (FDA) by end of 2025 PLYMOUTH MEETING, Pa. , Aug. 26, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, c...